Attached files
| file | filename |
|---|---|
| EX-10.4 - EX-10.4 - Lucira Health, Inc. | d19221dex104.htm |
| EX-10.19 - EX-10.19 - Lucira Health, Inc. | d19221dex1019.htm |
| EX-10.8 - EX-10.8 - Lucira Health, Inc. | d19221dex108.htm |
| EX-10.7 - EX-10.7 - Lucira Health, Inc. | d19221dex107.htm |
| EX-10.6 - EX-10.6 - Lucira Health, Inc. | d19221dex106.htm |
| EX-5.1 - EX-5.1 - Lucira Health, Inc. | d19221dex51.htm |
| EX-4.1 - EX-4.1 - Lucira Health, Inc. | d19221dex41.htm |
| EX-3.1 - EX-3.1 - Lucira Health, Inc. | d19221dex31.htm |
| EX-1.1 - EX-1.1 - Lucira Health, Inc. | d19221dex11.htm |
| S-1/A - AMENDMENT NO. 1 TO FORM S-1 - Lucira Health, Inc. | d19221ds1a.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Lucira Health, Inc.
Emeryville, California
We hereby consent to the use in the Prospectus constituting a part of this Registration Statement of our report dated November 20, 2020, except for the “Reverse Stock Split” paragraph of Note 2, as to which the date is February 1, 2021, relating to the financial statements of Lucira Health, Inc., which is contained in that Prospectus. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
| /s/ BDO USA, LLP |
| San Jose, California |
| February 1, 2021 |